Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention.

Currently, bladder cancer (BCa) evaluation depends mainly on traditional clinicopathological parameters encompassing tumor stage and grade, which will not reflect the behavior of the disease. Diverse molecular alterations are responsible for the heterogeneous course. The differences in molecular pathogenesis between non-invasive BCa and invasive BCa have been recognized.

WITHDRAWN: Molecular classification of colorectal cancer: Current perspectives and controversies.

This article has been withdrawn at the request of the editor. The authors have plagiarized part of a paper that had already appeared in ASCO EDUCATIONAL BOOK (2014), 91-99 (http://meetinglibrary.asco.

Pattern of Venous Thrombosis in Cancer Patients: Frequency and Survival Effect; Single Center Experience.

Venous thromboembolism (VTE) represents one of the most important causes of morbidity and mortality in cancer patients. This investigation was undertaken to investigate the natural history of VTE in the oncology center in a tertiary care hospital. We did a retrospective study on cancer patients who presented to King Abdullah Medical city in Holly capital; a tertiary care hospital; from May 2011 to June 2013.

Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer.

Background: This study evaluates the correlation between body mass index (BMI) and clinicopathological parameters of metastatic prostate cancer (MPC) and its impact on survival.

Method: During the study period, 71 MPC patients were eligible. Patients with BMI<25.

Target therapy in metastatic pheochromocytoma: current perspectives and controversies.

Most of the pheochromocytomas (PCCs) are benign neoplasms, but when they are malignant, they can be difficult to treat. Despite advances in diagnosis and imaging, it remains an untreatable tumor, when metastases develop. A deeper understanding of the alteration of the specific molecular pathways causing malignant PCCs might hopefully lead in the future to the development of multiple molecular-targeted therapies to treat it successfully.

End-of-life palliative chemotherapy: where do we stand?

Background: This study evaluates the use of palliative chemotherapy (PCT) and possible associated factors at the end of life.

Method: The study includes all advanced non hematological cancer patients who died in the King Abdullah Medical City during the period from January 2011 to April 2014. Demographic and disease features were registered.